A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

BACKGROUND: Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO)...

詳細記述

保存先:
書誌詳細
主要な著者: Noguchi, Masanori, Moriya, Fukuko, Suekane, Shigetaka, Ohnishi, Rei, Matsueda, Satoko, Sasada, Tetsuro, Yamada, Akira, Itoh, Kyogo
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2013
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3882108/
https://ncbi.nlm.nih.gov/pubmed/24373380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-613
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料